7Baggers

Aptevo Therapeutics Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20170630 20170930 20171231 20180331 20180630 20180930 20181231 20190331 20190630 20190930 20191231 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20221231 -16.82-9.01-1.26.6214.4322.2430.0537.87Milllion

Aptevo Therapeutics Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2022-12-31 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
  revenue-3,114,000 3,114,000 3,665,000 3,096,000 3,110,000 2,421,000 2,373,000 1,463,000 473,000 9,031,000 9,011,000 7,360,000 7,022,000 6,346,000 5,824,000 6,826,000 4,071,000 2,818,000 6,172,000 10,764,000 7,409,000 8,769,000 9,405,000 10,193,000 8,067,000 8,286,000 6,562,000 7,090,000 11,663,000 
  cost of revenue161,000 6,136,000 3,959,000 5,985,000 3,847,000 4,462,000 2,437,000 2,534,000 1,781,000 1,896,000 1,872,000 5,897,000 488,000 7,947,000 6,163,000 6,544,000 3,528,000 5,237,000 3,525,000 4,439,000 3,732,000 
  gross profit-3,275,000 3,114,000 3,665,000 3,096,000 3,110,000 2,421,000 2,373,000 1,463,000 473,000 2,895,000 5,052,000 1,375,000 3,175,000 1,884,000 3,387,000 4,292,000 2,290,000 922,000 4,300,000 4,867,000 6,921,000 822,000 3,242,000 3,649,000 4,539,000 3,049,000 3,037,000 2,651,000 7,931,000 
  operating expenses                             
  research and development4,674,000 4,866,000 4,543,000 4,367,000 4,722,000 5,362,000 4,912,000 4,494,000 4,440,000 5,614,000 9,125,000 7,733,000 7,285,000 8,899,000 8,574,000 9,713,000 8,199,000 9,186,000 7,175,000 6,788,000 5,913,000 6,667,000 7,114,000 7,636,000 8,101,000 7,407,000 7,712,000 10,506,000 9,101,000 
  sales, general and administrative                             
  total operating expenses7,684,000 8,725,000 7,705,000 7,846,000 8,832,000 9,309,000 9,192,000 7,709,000 7,280,000 10,606,000 15,601,000 14,271,000 14,615,000 15,476,000 15,514,000 16,736,000 15,791,000 17,743,000 14,648,000 15,543,000 16,460,000 15,375,000 18,794,000 16,494,000 17,521,000 21,549,000 16,225,000 20,961,000 19,033,000 
  operating income-7,684,000 -5,611,000 -4,040,000 -4,750,000 -5,722,000 -6,888,000 -6,819,000 -6,246,000 -7,280,000 -7,711,000 -10,549,000 -12,896,000 -11,440,000 -13,592,000 -12,127,000 -12,444,000 -13,501,000 -16,821,000 -10,348,000 -10,676,000 -9,539,000 -29,864,000 -71,254,000 -12,845,000 -12,982,000 -18,500,000 -13,188,000 -18,310,000 -11,102,000 
  net income30,352,000 -9,961,000 -6,272,000 -6,997,000 -7,932,000 -7,256,000 -7,053,000 -6,791,000 -6,803,000 -8,174,000 -6,924,000 -13,332,000 -12,018,000 -14,128,000 -12,562,000 -13,144,000 -13,854,000 -9,760,000 37,867,000 -11,189,000 -9,945,000 -14,946,000 -71,741,000 -12,838,000 -11,829,000 -17,898,000 -12,680,000 -17,716,000 -11,022,000 

We provide you with 20 years income statements for Aptevo Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Aptevo Therapeutics stock. Explore the full financial landscape of Aptevo Therapeutics stock with our expertly curated income statements.

The information provided in this report about Aptevo Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.